GLP-1 weight loss shots vs. pills, explained скачать в хорошем качестве

GLP-1 weight loss shots vs. pills, explained

The era of GLP-1 weight loss pills has officially begun. Novo Nordisk released a new, oral version of its GLP-1 weight loss drug Wegovy earlier this year. Rival Eli Lilly’s GLP-1 pill orforglipron is expected to be approved as early as this month.  A safe, effective weight loss pill was long a holy grail for the pharmaceutical industry. Injectable GLP-1 drugs like Ozempic have been blockbusters since they were approved to treat obesity a few years ago, but until now, an oral form of the medication has been elusive.  In this week’s STATus Report, host Alex Hogan explains why pills were so much harder to develop than injectables and why Novo and Lilly spent so much time and money developing oral GLP-1’s. STAT reporter and "The Readout LOUD" co-host Elaine Chen joins the conversation to discuss whether pills will alleviate some pricing and accessibility issues. 0:00 Intro 1:15 Why injections came before pills 1:52 Novo vs. Lilly rivalry 2:20 Differing approaches to pills 4:14 Could pills impact accessibility? 5:31 Will price cuts increase insurance coverage? 7:14 Are pills easier to manufacture? 8:28 Impact on tele-health companies? 9:34 Who has the advantage with pills? 11:11 Some eerily similar ads 12:15 Outro More from STAT: Become a subscriber: https://www.statnews.com/stat-plus/ Watch Full Episodes:    / @statnews   Newsletters: https://www.statnews.com/signup/ STAT events: https://www.statnews.com/stat-events/ Facebook:   / statnews   Twitter:   / statnews   Instagram:   / status_report_ig   Flipboard: rb.gy/3xnsxr STAT Reports: https://rb.gy/rexfwj STAT eBooks: https://rb.gy/eme3h5 ABOUT STAT: Founded in 2015, STAT is a global digital media brand that focuses on delivering fast, deep, and tough-minded journalism about the life sciences industries to over six million monthly site visitors and an additional 20 million readers on the Apple News app. STAT takes you inside academic labs, biotech boardrooms, and political backrooms, casting a critical eye on scientific discoveries, scrutinizing corporate strategies, and chronicling the roiling battles for talent, money, and market share. With an award-winning newsroom, STAT provides indispensable insights and exclusive stories on the technologies, personalities, power brokers, and political forces driving massive changes in the life sciences industry — and a revolution in human health.